系统性硬化症心血管磁共振异常与血清心脏生物标志物对心血管结局的预测价值
NT-proBNP>125 pg/mL与心血管结局风险显著升高相关(OR=5.335,p=0.040),ECV>29%呈趋势性关联(OR=4.347,p=0.073)。
要点
- NT-proBNP>125 pg/mL与系统性硬化症患者心血管结局风险升高相关(OR=5.335,p=0.040)。
- ECV>29%提示弥漫性心肌纤维化,与心血管结局呈趋势性关联(OR=4.347,p=0.073)。
- hs-TnI升高与更差的无事件生存呈趋势(X2=2.530,p=0.112),需更大样本验证。
核心结论
- 标准血清心脏生物标志物(尤其是NT-proBNP)及CMR心肌纤维化指标与系统性硬化症患者不良心血管结局相关。
主要发现
- 中位随访22个月,10例发生心血管结局,包括1例心肌炎伴收缩功能障碍和9例心律失常(3例非持续性室速、6例室上性心律失常)。
- NT-proBNP>125 pg/mL者心血管结局概率显著高于NT-proBNP正常者(X2=4.47,p=0.035)。
- ECV升高者与正常者相比(X2=2.659,p=0.103)、hs-TnI升高者与正常者相比(X2=2.530,p=0.112),无事件生存均呈更差趋势。
- 预测模型中NT-proBNP>125 pg/mL与心血管结局相关(OR=5.335,p=0.040),ECV>29%呈趋势(OR=4.347,p=0.073)。
关键数值与推荐
- 心血管结局定义为心肌炎、心律失常和/或超声心动图功能损害(包括收缩功能障碍和/或舒张功能障碍)。
- NT-proBNP>125 pg/mL为预测心血管结局的候选阈值(OR=5.335,p=0.040)。
- ECV>29%提示弥漫性纤维化,为预测心血管结局的候选阈值(OR=4.347,p=0.073)。
临床怎么用
- 对无临床心脏受累的系统性硬化症患者,可检测NT-proBNP辅助识别心血管结局高危者。
- CMR测量的ECV可作为心肌纤维化标志物纳入风险评估,但需更大样本验证其独立预测价值。
局限性
- ECV及hs-TnI的关联仅达趋势水平,未达统计学显著性。
- 随访时间中位22个月,长期预后需更长的纵向研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore the prognostic value of subclinical cardiovascular (CV) imaging measures and serum cardiac biomarkers in systemic sclerosis (SSc) for the development of CV outcomes of primary heart involvement (pHI). METHODS: Patients with SSc with no clinical SSc-pHI and no history of heart disease underwent cardiovascular magnetic resonance (CMR) imaging, and measurement of serum high-sensitivity-troponin I (hs-TnI) and N-terminal-pro-brain natriuretic peptide (NT-proBNP). Follow-up clinical and CV outcome data were recorded. CV outcomes were defined as myocarditis, arrhythmia and/or echocardiographic functional impairment including systolic dysfunction and/or diastolic dysfunction. RESULTS: Seventy-four patients with a median (IQR) age of 57 (49, 63) years, 32% diffuse cutaneous SSc, 39% interstitial lung disease, 30% Scl70+ were followed up for median (IQR) 22 (15, 54) months. Ten patients developed CV outcomes, comprising one patient with myocarditis and systolic dysfunction and nine arrhythmias: three non-sustained ventricular tachycardia and six supraventricular arrhythmias. The probability of CV outcomes was considerably higher in those with NT-proBNP >125 pg/mL versus normal NT-proBNP (X2=4.47, p=0.035). Trend for poorer time-to-event was noted in those with higher extracellular volume (ECV; indicating diffuse fibrosis) and hs-TnI levels versus those with normal values (X2=2.659, p=0.103; X2=2.530, p=0.112, respectively). In a predictive model, NT-proBNP >125 pg/mL associated with CV outcomes (OR=5.335, p=0.040), with a trend observed for ECV >29% (OR=4.347, p=0.073). CONCLUSION: These data indicate standard serum cardiac biomarkers (notably NT-proBNP) and CMR indices of myocardial fibrosis associate with adverse CV outcomes in SSc. This forms the basis to develop a prognostic model in larger, longitudinal studies.
引用
- Dumitru RB, Bissell LA, Erhayiem B, et al. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open. 2021. PMID: 34663635. doi:10.1136/rmdopen-2021-001689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。